Regulatory Approvals

FDA Approves First Drug to Treat the Full Range of Narcolepsy Type 1 Symptoms

By

U.S. FDA — The FDA approved Orzeyful (oveporexton) tablets for the treatment of narcolepsy type 1 in adults.

Read the original at U.S. FDA ↗

Auto-published by the finit.news Events monitor from U.S. FDA; summarized by AI and may contain errors — verify against the primary source. August 5, 2026.

By

Related Post

Regulatory Approvals

FDA Approves Oveporexton (Orzeyful) for Narcolepsy Type 1

Regulatory Approvals

FDA Approves Orzeyful for Narcolepsy Type 1 – respiratory

Regulatory Approvals

As FDA approves new marketing for nicotine pouches, some doctors sound alarms

Financial News For All

Labor

SSM Health appealing certification of union vote at St. Mary’s Hospital in Madison

Regulatory Approvals

FDA Approves Orzeyful for Narcolepsy Type 1 – respiratory

Regulatory Approvals

FDA Approves Oveporexton (Orzeyful) for Narcolepsy Type 1

Regulatory Approvals

FDA Approves Oveporexton for Narcolepsy Type 1, First Drug to Treat Full Range of NT1 Symptoms